Epigenetic Resensitization to Platinum in Ovarian Cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660

Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists

Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108

The Epigenomics of Cancer

Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515

MAP kinase signalling pathways in cancer

Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995

A systems biology approach for pathway level analysisPreprint

Drăghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichiţa, C., Georgescu, C., & Romero, R. J. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,263

Toll-like receptors and cancer

Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925

Platinum Resistance: The Role of DNA Repair Pathways

Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754

A cell biological view of Toll-like receptor function: regulation through compartmentalization

Barton, G. M., & Kagan, J. C. (2009) · Nature reviews. Immunology · doi:10.1038/nri2587 · Cited by 746

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Kantarjian, H. M., Oki, Y., Garcia‐Manero, G., Huang, X., O'Brien, S. M., Cortes, J. E., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z. E., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 684

DNA methylation analysis by pyrosequencing

Tost, J., & Gut, I. G. (2007) · Nature Protocols · doi:10.1038/nprot.2007.314 · Cited by 681

Decoding β-catenin associated protein-protein interactions: Emerging cancer therapeutic opportunities

Yan, Y., Gong, Y., Liang, X., Xiong, Q., Lin, J., Wu, Y., Zhang, L., Chen, H., Jin, J., & Luan, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189232 · Cited by 5

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma

van der Westhuizen, A., Knoblauch, N., Graves, M. C., Levy, R., Vilain, R. E., & Bowden, N. A. (2020) · Medicine · doi:10.1097/md.0000000000020705 · Cited by 5

Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm

Lee, D. Y. (2020) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-18 · Cited by 4

Epigenetic Modifications: Therapeutic Potential in Cancer

Sachan, M., & Kaur, M. (2015) · Brazilian Archives of Biology and Technology · doi:10.1590/s1516-8913201500132 · Cited by 4

Combined epigenetic and metabolic inhibition blocks platinum-induced ovarian cancer stem cell enrichmentPreprint

Sood, R., Sriramkumar, S., Muralikrishnan, V., Xiao, S., Wang, W., Hassel, C. A., Nephew, K. P., & O’Hagan, H. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435878 · Cited by 4

Epigenetic plasticity and chemoresistance in cancer: mechanisms, biomarkers, and translational opportunities for real-world evidence

Reichert, C. O., de Aquino, N. C., Callefi, V. D. C., Alves, I., Cattena, S., Santos, E. R., Vasconcelos, K., Culler, H. F., Lage, L. A. D. P. C., Rocha, V., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1786398 · Cited by 3

Apolipoprotein A-1 downregulation promotes basal-like breast cancer cell proliferation and migration associated with DNA methylation

Wang, C., Chen, S., Zhang, R., Chen, M., Yang, X., He, Y., Shangguan, Z., Mao, Q., Zhang, Z., & Ying, S. (2024) · Oncology Letters · doi:10.3892/ol.2024.14428 · Cited by 3

Cancer Stem Cells and Chemoresistance: Strategies to Overcome Therapeutic Resistance

Thomas, M. L., Coyle, K. M., Sultan, M., & Marcato, P. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_17 · Cited by 4

Outcome of Combining Epigenetic Drugs with Other Treatments in the Clinic

Raha, P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00040-5 · Cited by 3

Distinct promotor methylation at tumor suppressive genes in ovarian cancer stromal progenitor cells and ovarian cancer and its clinical implication.

Ho, C., Yen, T., Chien, T.-Y., & Huang, S. (2022) · PubMed Central · Cited by 3

HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer

Li, X., Zheng, Z., Zhou, W., Huang, H., Zhou, Y., Xu, Q., Zhu, X., & Teng, Y. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01424-1 · Cited by 3

Espoirs et promesses de la méthylation de l’ADN et des histones comme cibles anticancéreuses

Bon, C., Erdmann, D., Halby, L., & Arimondo, P. B. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.08.001 · Cited by 3

Epigenetics and Cancer

Baylin, S. B. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00005-6 · Cited by 3

DNA Methylation and Carcinogenesis: Current and Future Perspectives

Patil, V., & Herceg, Z. (2019) · Springer eBooks · doi:10.1007/978-981-13-8958-0_7 · Cited by 3

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Landon, B. V., Boland, J. L., Hendrickson, A. E. W., Armstrong, D. K., Winterhoff, B. J. N., Wehr, J., Annapragada, A. V., Cherry, C., Balan, A., Kaleka, G., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01404-0 · Cited by 2

Targeting epigenetic networks to overcome cisplatin resistance in ovarian cancer: from mechanisms to clinical translation

MaoYan, T., Wang, Y., Xie, Y., Li, J., Ding, D., Li, C., Chen, Q., & Han, F. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02005-0 · Cited by 2

Ovarian cancer: Targeted therapies and mechanisms of resistance

Sarvepalli, D., Rashid, M. U., Zafar, H., Jehanzeb, S., Zahid, E., & Ahmad, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00014-9 · Cited by 2

Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study

Kim, D. H., Kong, J. H., Hong, J., Byun, J. M., Shin, D.-Y., Koh, Y., Kim, I., Park, J., Do, Y. R., Kim, J., et al. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251349361 · Cited by 2

Genome profiling of mismatch repair genes in eight types of tumors

Wang, S., Guan, G., Zou, C., Guo, Q., Cheng, W., Shen, S., Fang, D., Wu, A., Li, G., & Zhu, C. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1922160 · Cited by 2

Behandlung von Patienten mit cisplatinrefraktären Keimzelltumoren

Koychev, D., Honecker, F. U., Bokemeyer, C., & Albers, P. (2013) · Der Onkologe · doi:10.1007/s00761-013-2477-1 · Cited by 2

Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors

Anastasio, G., Felaco, M., Lamolinara, A., Pizzo, F., Cacciagrano, E., Mottini, C., Mutarelli, M., Modugno, F. D., Iezzi, M., & Cardone, L. (2025) · iScience · doi:10.1016/j.isci.2025.111842 · Cited by 1

DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment

Vuong, T. T., Sood, R., Zhang, S., Metcalfe, T. X., Han, R. Y., Nephew, K. P., & O’Hagan, H. M. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0149 · Cited by 1

Targeting T-cell exhaustion and tumour immune evasion: a review of emerging strategies

Saltis, L., & Mun, L. J. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156638 · Cited by 1

Molecular Genetic Findings in Small Bowel Neuroendocrine Neoplasms: A Review of the Literature

Miller, H. C., Kidd, M. S., Castellano, L., & Frilling, A. (2015) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.41 · Cited by 1

Epigenetic Therapies in Solid Tumours: From Preclinical Models to Clinical Trial Results

Brown, R. E., Lohmeyer, J. K., Graham, J., & Glasspool, R. M. (2013) · Springer eBooks · doi:10.1007/978-3-642-38404-2_13 · Cited by 1

Therapeutic implications for ovarian cancer emerging from the Tumor Cancer Genome Atlas

Verschraegen, C. F., Lounsbury, K. M., Howe, A. K., & Greenblatt, M. S. (2015) · Translational Cancer Research · doi:10.21037/3931 · Cited by 1

Episensitization

Oronsky, B. T., Oronsky, A. L., Lybeck, M., Oronsky, N. C., Scicinski, J. J., Carter, C. A., Fanger, G. R., & Reid, T. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00016-3 · Cited by 1

Clinical Applications of Epigenomics

McDevitt, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800140-0.00013-3 · Cited by 1

Molecular Assessment of Ovarian Cancer and Translation to Clinical Management

Silvestris, E., D’Oronzo, S., Passarelli, A. M., Pellè, E., Nola, R. D., Palmirotta, R., & Silvestris, F. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00035-1 · Cited by 1

Decitabine: A Historical Review of the Development Process of an Epigenetic Drug

Zamur, C., & Topal, U. (2020) · Integrative Journal of Medical Sciences · doi:10.15342/ijms.7.202 · Cited by 1

Inferences of carboplatin response-related signature by integrating multiomics data in ovarian serous cystadenocarcinoma

Yan, J., Liu, M., Ma, Y., Le, K., Dong, B., & Li, G. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702221083254 · Cited by 1

Epigenetic Pharmacology

Burkhart, R. A., Sharma, A. R., & Ahuja, N. (2018) · Springer eBooks · doi:10.1007/978-1-4939-7193-0_69 · Cited by 1

3D culture adds an extra dimension to targeted epigenetic therapies

Özeş, A., & Nephew, K. P. (2013) · Cell Cycle · doi:10.4161/cc.25551 · Cited by 1

Overcoming Immune System Evasion by Personalized Immunotherapy

Soares, K. C., Zheng, L., & Ahuja, N. (2014) · Personalized Medicine · doi:10.2217/pme.14.45 · Cited by 1

Therapeutics and DNA Methylation Inhibitors

Bhalla, S., & Navada, S. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00033-8 · Cited by 1

Epigenomics of Ovarian Cancer and Its Chemoprevention

Koukoura, O., Sifakis, S., Goutsias, N., Gkorezi-Ntavela, I., & Hajiioannou, J. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812494-9.00016-0 · Cited by 1

Novel Indications of Epigenetic Therapy in Ovarian Cancer

Griffiths, C., Bilbao, M., Krill, L. S., & Ostrovsky, O. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98187 · Cited by 1

Chemoresistance, Dormancy and Recurrence in Platinum Drug Therapy of Ovarian Cancers

Kalir, T., & Kohtz, D. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-9325-4_7 · Cited by 1

Therapeutics and DNA methylation inhibitors

Navada, S. C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00014-1 · Cited by 1

Characterization of novel epigenetic targets in ovarian cancer

Wang, Z. (2014) · Corpus Université Laval (Université Laval) · Cited by 1

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancerPreprint

Martins, F. C., Couturier, D., de Santiago, I., Sauer, C. M., Vias, M., Angelova, M., Sanders, D. A., Piskorz, A., Hall, J. A. M., Hosking, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.04.325365 · Cited by 1

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant modelsPreprint

Nguyen, L. L., Watson, Z. L., Ortega, R., Woodruff, E. R., Jordan, K. R., Iwanaga, R., Yamamoto, T. M., Bailey, C. A., Jeong, A. D., Guntupalli, S. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.23.529773 · Cited by 1

Identificação de alvos moleculares associados à resistência e a sensibilidade aos antitumorais carboplatina e análogos de rebecamicina utilizando Saccharomyces cerevisiae como modelo celular

de Sousa, G. F. (2013) · doi:10.11606/d.9.2013.tde-27022014-103617

Dosing – When Less is More

Pandiyan, K., Jones, P. A., & Baylin, S. B. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782628484-00249

Who will Benefit from Epigenetic Drugs?

Verhelle, D., & Shields, D. J. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782628484-00230

Pharmacoepigenomics and Pharmacovigilance in Gynecological Cancers

Sun, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-32907-9_2

Cancer Stem Cells as New Therapeutic Targets for Ovarian Cancer

Wang, Y., Fang, F., Condello, S., Matei, D. E., & Nephew, K. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803892-5.00009-7

The Role of Cbx Proteins in Human Benign and Malignant Hematopoiesis

Jung, J., Schepers, H., Lazare, S., Buisman, S. C., Weersing, E., Dethmers-Ausema, B., Klauke, K., Bystrykh, L., & de Haan, G. (2016) · Blood · doi:10.1182/blood.v128.22.2651.2651

A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy

Baylin, S. B. (2017)

Future Perspective of DNA and Histone Methylation as Cancer Targets

Takeshima, H., & Ushijima, T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_21 · Cited by 1

DNA Methylation and Histone Modifications in Autoimmunity

Banik, D., Chiappinelli, K. B., & Villagra, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00003-9

Development of immune-modulatory RNAS to regulate RIG-I-like receptors mediated antiviral immune response for therapy and vaccination

Yong, H. Y. (2018) · doi:10.32657/10220/47467

Epigenetics

Pepin, J. T., Cárdenas, H., Nephew, K. P., & Matei, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00003-3

Epigenetics in diagnosis, prognosis and therapy

Qazi, S., & Sharma, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819753-0.00019-2

Clinical utility of solid tumor epigenetics

Demirdizen, E., Taranda, J., & Turcan, Ş. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00013-x

Epigenetic biomarker and drug development in gynecological cancers

Su, P., Chen, L., Huang, R., Wen, K., Liew, P., & Lai, H.-C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823008-4.00013-5

Epigenetic Pharmacology

Burkhart, R. A., Sharma, A. R., & Ahuja, N. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_69-1

Epigenetic therapy and DNA damage response

Baretti, M., & Azad, N. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91081-1.00009-1

Epigenetics in Cancer Biology

Stein, R. A., & Deverakonda, A. N. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_86

Data from Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation

Wang, W., Fang, F., Özeş, A., & Nephew, K. P. (2023) · doi:10.1158/1535-7163.c.6543522.v1

Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

Odunsi, K. O., Matsuzaki, J., James, S. R., Mhawech-Fauceglia, P. Y., Tsuji, T., Miller, A., Zhang, W., Akers, S. N., Griffiths, E. A., Miliotto, A. J., et al. (2023) · doi:10.1158/2326-6066.c.6548066.v1

Epigenetic Contributions to Human Cancer

Herman, J. G., & Baylin, S. B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm006

Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response

Marchi, E., Pal, I., Manavalan, J. S., Jayappa, K. D., & O’Connor, O. A. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch28

Additional file 1 of Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer

Feng, L., Yan, B., Huang, Y.-Z., & Li, L. (2021) · Figshare · doi:10.6084/m9.figshare.15033175

Introduction to Drug Discovery in Epigenetics

Jones, P. A., & Liu, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-00001

Introduction to Epigenetic Drug Discovery

(2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674916-part1

Re-sensitization of cancer cells in nonsolid tumors

Kumar, A., Arya, D. K., Pandey, P. K., Kanaujiya, S., & Rajinikanth, P. S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33343-9.00006-5

Targeting TET enzymes in ovarian cancer: epigenetic regulation, chemoresistance, and therapeutic opportunities

Shruptha, P., Poyya, J., Vasudevan, T. G., & Satyamoorthy, K. (2025) · Epigenomics · doi:10.1080/17501911.2025.2595912 · Cited by 1

Additional file 1 of Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer

Zou, R., Jiang, Q., Luo, X., Chen, M., Yuan, L., & Yao, L. (2024) · Figshare · doi:10.6084/m9.figshare.26647377

Additional file 2 of Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer

Zou, R., Jiang, Q., Luo, X., Chen, M., Yuan, L., & Yao, L. (2024) · Figshare · doi:10.6084/m9.figshare.26647380

Additional file 1 of HOXB2 promotes cisplatin resistance by upregulating lncRNA DANCR in ovarian cancer

Li, X., Zheng, Z., Zhou, W., Huang, H., Zhou, Y., Xu, Q., Zhu, X., & Teng, Y. (2024) · Figshare · doi:10.6084/m9.figshare.25998581

Additional file 12 of Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer

Soto, J. A., Rodríguez‐Antolín, C., Vera, O., Pernía, O., Esteban‐Rodríguez, I., Dolores Diestro, M., Benitez, J., Sánchez-Cabo, F., Alvarez, R., de Castro, J., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16530177

Additional file 1 of Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level

Takeshima, H., Yoda, Y., Wakabayashi, M., Hattori, N., Yamashita, S., & Ushijima, T. (2020) · Figshare · doi:10.6084/m9.figshare.12986413

Additional file 1 of Epigenetic priming improves salvage chemotherapy in diffuse large B-cell lymphoma via endogenous retrovirus-induced cGAS-STING activation

Liu, J., Min, S., Kim, D., Park, J., Park, E., Koh, Y., Shin, D.-Y., Kim, T. K., Byun, J. M., Yoon, S.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26586501

Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer Patients

Farid, E. A., Zhang, S., Fu, Z., Coon, C. M., Matei, D. E., Jalal, S. I., & Nephew, K. P. (2026) · Pharmaceuticals · doi:10.3390/ph19040542

Natural Compounds as Epimodulators in Epithelial Ovarian Cancer

Lizarazo-Taborda, M. D. R., Villegas-Pineda, J. C., Parada, H., Galvis, F., & Soto, J. (2026) · Epigenomes · doi:10.3390/epigenomes10020023

Integrated Epigenomic and Transcriptomic Analysis Identifies Diagnostic Biomarkers for Endometrial Cancer

Wang, H., & Wang, F. (2026) · Stem Cells International · doi:10.1155/sci/5505750

À la rencontre des "readers" de l'ADN méthylé

Erdmann, D. (2021) · theses.fr (ABES) · doi:10.70675/f2b76a23z3f81z46f4z85a7z4abc4c194eae

Whole Exome Sequencing Reveals Potential Single Nucleotide Polymorphisms and Copy Number Variations in 26 Sporadic Patients with Immature Teratoma

Liu, Y., Jia, Y., Du, N., Li, Y., Wang, C., & Kang, S. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s586914

The Role of Epigenetics in Cancer Progression

Biswas, P., Sridhar, B., Saha, A., Sudha, M., & Kulkarni, M. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814113126010006

From Epigenetic Dysregulation to Therapeutic Reprogramming in Endometrial Cancer: A State–Response Framework for Treatment Resistance

Srivastava, M., Singh, S., Kumar, P., Moond, N., Chouhan, A., Mann, K., Kumari, S., Banerjee, M., & Kushwah, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104371 · Cited by 1

Decitabine inhibits the malignant transformation of oral potentially malignant disorders by upregulating SOX1 expression via demethylation to modulate the wnt pathway in a male rat model

Wang, T., Wang, P., Zhan, X., Zhang, H., Sun, P., Guo, Y., Yuan, M., Jiao, M., Chi, J., Wang, K., et al. (2026) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2026.106628

Half-Sandwich Ir(III) and Ru(II) Complexes Featuring a Coumarin-Based Chelating Core for Mitochondrial-Targeted Anticancer Activity

Guo, L., Liang, P., Jia, W., Zhang, X., Chen, Y., Zhang, M., Qi, L., Li, S., & Liu, Z. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6c01471

Development and validation of an epigenetic score for homologous recombination deficiency based on genome-wide DNA methylation profiling in ovarian cancer

Zhu, H., He, W., Zhang, S., Cao, H., Shen, M., Wan, X., & Wu, Q. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102626

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies

Pietrasik, Z., Kapała, M., Pietrasik, J., Stefaniak, M., Szubert, S., Książek, K., & Mikuła‐Pietrasik, J. (2026) · Cancers · doi:10.3390/cancers18162623

DNA methylation profiling and growth inhibitory effects of decitabine in canine hemangiosarcoma cell linesPreprint

Kanomata, R., Suzuki, T., Tanaka, S., Kishimoto, K., Goto, T., Maharani, A., Chankow, K., Kesdangsakonwut, S., Kimura, T., Yamazaki, J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10623493/v1

Epigenetic mechanisms and clinical translation in ovarian cancer: from molecular pathways to precision therapy

Alsamman, K. (2026) · Bioscience Reports · doi:10.1042/bsr20250409

Sensitizing nanomedicine for platinum-resistant ovarian cancer

Lee, D. H.-Y., Lee, W. E., & Bach, H. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2738705

Beyond Platinum Resistance: Reconsidering Platinum Sensitivity as a Dynamic Phenotype in Ovarian Cancer

Goyeneche, A. A., Rosato, A. E., Rosato, R. R., & Telleria, C. M. (2026) · Cancers · doi:10.3390/cancers18203295

MicroRNA and Cancer Drug Resistance

Chen, D., & Nakshatri, H. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8065-6_16

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer

Fang, F., Balch, C., Schilder, J. M., Breen, T., Zhang, S., Shen, C., Li, L., Kulesavage, C., Snyder, A. J., Nephew, K. P., et al. (2010) · Cancer · doi:10.1002/cncr.25204 · Cited by 176

A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).

Matei, D. E., Shen, C., Fang, F., Schilder, J. M., Li, M., Arnold, A., Zeng, Y., Pilrose, J. M., Kulesavage, C., Balch, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.5011 · Cited by 14

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer

Glasspool, R. M., Brown, R. E., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.116 · Cited by 125

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs

Fang, F., Cárdenas, H., Huang, H., Jiang, G., Perkins, S. M., Zhang, C., Keer, H. N., Liu, Y., Nephew, K. P., & Matei, D. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1492 · Cited by 110

Decitabine reactivated pathways in platinum resistant ovarian cancer

Fang, F., Zuo, Q., Pilrose, J. M., Wang, Y., Shen, C., Li, M., Wulfridge, P., Matei, D. E., & Nephew, K. P. (2014) · Oncotarget · doi:10.18632/oncotarget.1961 · Cited by 49